FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells-Reference-Cited by-同舟云学术

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells

Published:2014-08-07 Issue:11 Volume:63 Page:1189-1197
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Braga Walter Moises Tobias,da Silva Bruna Raphaeli,de Carvalho Ana Carolina,Maekawa Yumi H.,Bortoluzzo Adriana Bruscato,Rizzatti Edgar Gil,Atanackovic Djordje,Colleoni Gisele Wally Braga

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-014-1589-9/fulltext.html

Reference37 articles.

1. Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138:563–579. doi: 10.1111/j.1365-2141.2007.06705.x

2. Prabhala RH, Neri P, Bae JE, Tassone J, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 107:301–304. doi: 10.1182/blood-2005-08-3101

3. O’Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nat Med 10:801–805. doi: 10.1038/nm0804-801

4. Adeegbe DO, Nishikawa H (2013) Natural and induced T regulatory cells in cancer. Front Immunol 4:190. doi: 10.3389/fimmu.2013.00190

5. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok J (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105:20410–20415. doi: 10.1073/pnas.0810114105

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in immune subsets during chemotherapy as prognosis biomarkers for multiple myeloma patients by longitudinal monitoring;Immunologic Research;2024-09-10

2. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation;Blood;2024-04-18

3. Role of Immune Cells and Immunotherapy in Multiple Myeloma;Life;2024-04-01

4. What happens to regulatory T cells in multiple myeloma;Cell Death Discovery;2023-12-21

5. Immune checkpoint inhibitors for multiple myeloma immunotherapy;Experimental Hematology & Oncology;2023-11-28